NC Biotech Center Awards FLAG THerapeutics $500k

The North Carolina Biotechnology Center announced a $500,000 Strategic Growth Loan to FLAG Therapeutics. The Strategic Growth Loan (SLG) is designed to help North Carolina life science product companies reach specific and meaningful milestones that will enable them to obtain further funding from investors and/or to commercialize their products. The award supports an Investigational New Drug filing with the U.S. Food and Drug Administration and completion of a Phase 1 safety study of a novel small molecule for treating glioblastoma, a malignant brain tumor with an extremely poor prognosis.  

Read More
Aaron White
A Lifetime of Cancer Research

University’s Largest Licensing Agreement— with Alumnus— Puts Anti-Cancer Compounds on Path to Commercialization

The largest licensing agreement in Duquesne University’s history brings the fruits of Dr. Aleem Gangjee’s career-long fight against cancer all the closer to commercialization.

“This is a unique opportunity for one of our researchers to join forces with an alumnus who can further his research efforts and attempt to bring these compounds to market,” says Pharmacy Dean J. Douglas Bricker.

Read More
Aaron White
Licensing Agreement with Duquesne University

FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds

Agreement encompasses a broad IP estate and library of anti-cancer compounds engineered for improved efficacy and tolerability

Read More
Aaron White